El acceso a los medicamentos: conflictos entre derechos de propiedad intelectual y protección de la salud pública / O acesso aos medicamentos: conflitos entre direitos de propriedade intelectual e proteção da saúde pública / The access to drugs: conflicts between intellectual property and public health protection

Entre los mayores obstáculos que enfrenta en todo el mundo el acceso a los medicamentos se encuentran las cuestiones relativas a los derechos de propiedad intelectual y la falta de competencia, unido al retardo y postergación en la generación de investigación y desarrollo (I+D) sobre aquellas enfermedades que afectan de manera importante a la población de países en desarrollo y países menos adelantados. En este trabajo se analiza el fortalecimiento de la patente farmacéutica contemplada en el Acuerdo sobre los Aspectos de los Derechos de Propiedad Intelectual (ADPIC) de la Organización Mundial de Comercio (OMC) y el actual régimen de incentivo imperante para medicamentos nuevos, sus consecuencias y actuales conflictos. En ellos suelen enfrentarse los intereses de países desarrollados, presionados por una poderosa industria farmacéutica, con los intereses de países en desarrollo y países menos adelantados.

Topics related to intellectual property rights and lack of competency are found among the major obstacles facing the access to drugs in the world, together with the delay and postponement in the generation of R+D about those diseases affecting disproportionately to the population of developing countries and least developed countries. In this study, the strengthening of pharmaceutical patents included in the Agreement on trade-related aspects of intellectual property rights of the World Trade Organization (WTO) and the current prevailing incentive towards new drugs, their consequences and current conflicts are analyzed. In these, generally, the developed countries interests are confronted -pressed by a powerful pharmaceutical industry- with the interests of developing countries and least developed countries.

Entre os maiores obstáculos que enfrenta em todo o mundo, o acesso aos medicamentos se encontram as questões relativas aos direitos de propriedade intelectual e a falta de competência, aliado ao retardo e postergação na geração de I+D sobre aquelas enfermidades que afetam de maneira desproporcionada a população dos países em desenvolvimento e países menos adiantados. Neste trabalho se analisa o fortalecimento da patente farmacêutica contemplada no Acordo sobre os Aspectos dos Direitos de Propriedade Intelectual (ADPIC) da Organização Mundial de Comércio (OMC) e o atual regime de incentivo imperante para medicamentos novos, suas consequências e atuais conflitos. Neles devem ser enfrentados os interesses de países desenvolvidos -pressionados por uma poderosa indústria farmacêutica- com os interesses de países em desenvolvimento e países menos adiantados.

The Doctrine of the Mean in International Protection of Pharmaceutical Intellectual Property / 中国医学伦理学

There are multiple rights conflicts in the international protections of pharmaceutical intellectual property,among which the most prominent is the confrontation of the patent right and the right of life and health.This article tries to examine the pharmaceutical intellectual property rights with an ethical perspective,and resolve the conflict and moral dilemma in its international protection using the doctrine of the mean.When the pharmaceutical patent which is serviced as privacy and property rights,doesn't conflict with other more important rights,we should protect pharmaceutical patent and try our best to promote the attainment of it.Otherwise,the patent right should be replaced by the right of life and health.In practice,the international protection of pharmaceutical intellectual property should respect the difference principle,establish the appropriate price different system of pharmaceutical patent and carry forward humanism to safeguard the right of life and health.

Our Opinion on the Execution of the Pharmaceutical Patent Law in China / 中国药房

In view of the fact that the Pharmaceutical Patent Law will be put into effect in China,the authors suggest that the development of new drugs in China should be relied mainly rather on creating than on copying. However,some of the effective drugs should be still modelled on foreign products. We should pay great attention to the research work on pharmaceutical preparations and the development of Chinese patent medicine, intermediates of preparation and reagents.